Summary
GBI Research, the
leading business intelligence provider, has released its latest research,
"Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing
Uptake of Novel Drug Classes to Drive Market Growth", which provides
insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China,
India, Japan and Australia. The report estimates the market size for 2013 and
provides a forecast until 2020, and covers disease epidemiology, treatment
algorithms, and treatment use patterns. It also provides in-depth analysis of
the pipeline molecules, clinical trial failure rates, and recent deals. The
report has been built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis carried out by
GBI Research's team of industry experts.
Browse full report on: http://www.radiantinsights.com/research/type-2-diabetes-therapeutics-in-asia-pacific-markets-to-2020-increasing-uptake-of-novel-drug-classes-to-drive-market-growth
In 2013, the value of
the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5
billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of
7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the
anticipated approval of products in relatively novel treatment classes, such as
Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4)
inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as
the growth of the prevalence population in the APAC region, particularly in
India and China.
Scope
The report analyzes the
treatment use patterns, market characterization, pipeline analysis and key
licensing and co-development deals of the type 2 diabetes in the APAC markets
of China, India, Japan, and Australia.It includes -
- A brief introduction
to type 2 diabetes, including its pathophysiology, etiology, diagnosis and
treatment algorithms
- In-depth analysis of
currently marketed drugs for type 2 diabetes, including analysis of their
safety, efficacy, treatment patterns, and strengths and weaknesses, as well as
a heat map comparing them in terms of safety and efficacy
- A comprehensive review
of the pipeline for type 2 diabetes, including individual analysis of a number
of late
-stage pipeline drugs
that are likely to enter the market during the forecast period; the pipeline is
analyzed by Phase distribution, molecule type, program type, mechanism of
action and molecular target
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment